First human study of a new Alzheimer's drug
Part of Brain & nervous system, Mental health clinical trials.
This study tests an experimental drug (LY3954068) for people with early Alzheimer's disease. It aims to see if the drug is safe and may slow memory loss. You'll need a PET scan to measure tau protein in the brain and have a study partner who can help attend appointments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mild to early Alzheimer's symptoms (memory changes for at least 6 months) and a diagnosis of early symptomatic Alzheimer's disease.
- You have a study partner (someone who knows you well) who can spend at least 10 hours a week with you and come to appointments.
- You are willing to have a PET scan that checks for tau protein in your brain (a sign of Alzheimer's).
- You have not had previous treatments targeting tau protein or certain other Alzheimer's therapies in the past year.
- You are generally healthy and do not have serious or unstable medical conditions like heart, liver, or kidney problems.
- You are not pregnant, breastfeeding, or planning to become pregnant, and if male, you agree to use contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.
This study tests an experimental drug called LY4405094 in healthy people and in people with Alzheimer's disease. It aims to see if the drug is safe and how the body handles it, which could lead to new treatments for Alzheimer's.
This study tests several new experimental medications that target amyloid plaques, the protein clumps linked to Alzheimer's disease. It aims to find out if these treatments are safe and well-tolerated in people with early-stage Alzheimer's and in healthy volunteers.
This trial tests a new medicine called LY4006895 in two groups: healthy volunteers and people with early symptomatic Alzheimer's disease. It aims to see how the drug works in the body and if it might help memory and thinking.
This study tests an investigational medication in healthy volunteers and people with Alzheimer's disease. It aims to understand how the drug works and its safety.
This trial looks for signs of Alzheimer’s disease in the brain by using memory and thinking tests, and related study procedures. It may help researchers find better ways to identify Alzheimer’s-related changes earlier.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.